diabetestalk.net

Lantus Biosimilar

Share on facebook

Biosimilars Are Beginning To Bite For Sanofi

Biosimilars are beginning to bite for Sanofi French drugmaker Sanofi reported higher-than-expected sales growth of 5.5% in the second quarter versus the same period a year prior, boosted by double-digit jumps in revenues from its Genzyme unit and vaccines business. Sales from its diabetes and cardiovascular business, however, fell by 15% due to biosimilar competition in Europe and formulary exclusions in the U.S. Sanofirecently launched Dupixent(dupilumab) and Kevzara (sarilumab), two immunology drugs it expects to be a cornerstone of future growth. While Dupixent only brought in sales of 26 million, Sanofi noted that over 5,100 physicians had prescribed Dupixentas of July 26. While overall sales might be up, steepening declines from its diabetes and cardiovascular business continues to weigh on the drugmaker. Sales of insulin glargine (Lantus and Toujeo) were down 23.9% in the U.S., following the exclusion of Lantus from both CVS' and United Health's formularies. The launch of Eli Lilly's Lantus biosimilar Basaglar in the U.S. last December has also had an impact, albeit small. Merck & Co.'s Lusduna Nexvue , while currently on hold under the Hatch-Waxman Act, could pose a future Continue reading >>

Share on facebook

Popular Questions

  1. Oildog

    On occasion if I eat something, about 20 minutes later I will throw up. Its not that I feel sick either, I just start salivating excessively. It seems to happen less if I'm eating proteins. Too many carbs may be one cause. More often this happens if I've skipped a meal. Anyone else experience this or have suggestions?

  2. ElkHunter

    Yes, it happens to me all the time. The doctor said it was common with diabetics and not necessarily caused by meds. She prescribed Ondansetron 8mg to me. I take one when I feel it coming on and it works quick so I don't get sick. Just one tablet, every now and then. I think I've used about 4 in the last 3-4 weeks.
    __________________
    [B][COLOR="Red"]"No Copyrighted Material."[/COLOR][/B]
    [URL="http://www.city-data.com/"][COLOR="SeaGreen"]CD Home page[/COLOR][/URL], [URL="http://www.city-data.com/forumtos.html"][COLOR="seagreen"]TOS (Terms of Service)[/COLOR][/URL], [URL="http://www.city-data.com/forum/faq/107997-search-function-using-search-function.html"][COLOR="SeaGreen"]How to Search,[/COLOR][/URL] [URL="http://www.city-data.com/forum/faq/"][COLOR="SeaGreen"]FAQ's[/COLOR][/URL], [URL="http://www.city-data.com/forum/faq/70589-guide-guide-city-data-posting.html"][COLOR="SeaGreen"]Guide[/COLOR][/URL]
    [URL="http://www.city-data.com/forum/wyoming/"]Wyoming[/URL], [URL="http://www.city-data.com/forum/montana/"]Montana[/URL], [URL="http://www.city-data.com/forum/north-dakota/"]North Dakota[/URL], [URL="http://www.city-data.com/forum/south-dakota/"]South Dakota[/URL], [URL="http://www.city-data.com/forum/guns-hunting/"]Guns and Hunting[/URL]

  3. Oildog

    Thanks Elk. I'll talk to the doc at my next appointment. Its weird just sitting there and then I start salivating like a dog at a bacon store.

  4. -> Continue reading
read more close
Share on facebook

Gc Pharma Announces Approval For Lantus Biosimilar In Korea

GC pharma announces approval for Lantus biosimilar in Korea GC pharma announces approval for Lantus biosimilar in Korea The company plans to launch Glarzia Prefilled Pen, a Lantus biosimilar developed by Indian drug maker Biocon, in the third quarter this year Koreas GC Pharma announced that it has attained regulatory approval to sell a copy version of Sanofis blockbuster insulin Lantus- Glarzia Prefilled Pen in Korea. This is product is the second Lantus biosimilar after Boehringer Ingelheims Basaglar. The company plans to launch Glarzia Prefilled Pen, a Lantus biosimilar developed by Indian drug maker Biocon, in the third quarter this year, an official said on March 8. Under a license deal in 2016, GC Pharma holds exclusive sales marketing rights for Glarzia in Korea. The Ministry of Food and Drug Safety gave the sales license to GC Pharma for Glargia Prefilled Pen, which will be an import version of Lantus biosimilar by Indias Biocon. Sanofis Lantus is a blockbuster antidiabetic injection in the insulin market, selling more than 30 billion won ($282 million) in 2017, according to UBIST data. Glarzia will now compete against Basaglar, another long-acting insulin biosimilar from Continue reading >>

Share on facebook

Popular Questions

  1. Alfred

    Hello!
    How long after the expiration date are the test strips still good for?
    My strips expired December 11th.
    Thank you!

  2. Squeaky and KT (GA)

    I've used expired Confirm/Micro strips without an problem - can't tell you those will be fine, just sharin' my experience with them.

  3. Deb & Wink

    I've used test strips that were still in their foil packet for up to a year past the labeled expiration date. Your mileage may vary.

  4. -> Continue reading
read more close
Share on facebook

Mylan And Biocon Get Approvals For Biosimilar Insulin Glargine In Europe And Australia

Mylan and Biocon Get Approvals for Biosimilar Insulin Glargine in Europe and Australia The European approval marks the first approval for a biosimilar in that region resulting from the companies joint portfolio. Mylan and Biocon have received marketing authorization approval from the European Commission (EC) for Semglee 100 units/mL 3-mL prefilled disposable pen, a biosimilar insulin glargine for treating diabetes, the companies announced on Mar. 27, 2018. Semglee is the first biosimilar resulting from Biocon and Mylan's joint portfolio to be approved in Europe. In addition, the companies received approval for the product in Australia from the Therapeutic Goods Administration (TGA). "We are excited to be able to bring Mylan and Biocon's biosimilar insulin glargine to Europe and Australia where millions of people are currently living with diabetes, and we are committed to continuing to bring high quality, more affordable biosimilar products to markets around the world. The investments that we have made to develop and manufacture a leading portfolio of complex products, including Semglee, is one way that we are delivering on our commitment to expand access to high quality medicine," Continue reading >>

Share on facebook

Popular Questions

  1. Eric

    Fiasp is the newest insulin from Novo Nordisk (the makers of NovoLog,Tresiba, & Levemir).
    Fiasp stands for "Faster-acting Insulin Aspart”. It is supposed to be much faster than the current rapids like NovoLog, Humalog, and Apidra.
    Fiasp is approved many other places in the world, but not yet approved or available in the United States.
    So I got some.

    I’ll let you know if it lives up to its hype…

  2. docslotnick

    @Eric Where did you get that??? I am so envious/jealous of you.

    I need, I want, gimme.

  3. Eric

    docslotnick:
    Where did you get that???
    Talk to me Doc, I can walk you through what I did.

    The funny thing is, I have only used a little bit so far. My BG has been so low, I haven’t really had an opportunity to use a bunch yet.

  4. -> Continue reading
read more close

No more pages to load

Related Articles

  • Humalog Biosimilar

    FDA Grants Tentative Approval to Follow-On Insulin Lispro, Admelog The FDA has grantedtentative approval of Sanofis follow-on insulin lispro injection, Admelog. Referenced on the originator product, Humalog, Sanofis insulin lispro is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with diabetes. The FDA has granted tentative approval of Sanofis follow-on insulin lispro injection, Admelog. Referenc ...

    diabetes May 26, 2018
  • Biosimilar Insulin

    Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above. The originator product, Sanofi’s Lantus (insulin glargine), was approv ...

    insulin Mar 14, 2018
  • Insulin Biosimilar

    Yes—and no. In December 2015, the Food and Drug Administration (FDA) approved the long-acting human insulin analog Basaglar (insulin glargine injection). Basaglar is similar to the insulin glargine injection Lantus, and the approval of Basaglar relied in part on the FDA’s finding of safety and effectiveness for Lantus. In Europe, the analogous product is considered to be a biosimilar. In the United States, Basaglar is not approved as a biosim ...

    insulin May 26, 2018
  • Lantus Biosimilar

    Twitter Summary: 1st ever “biosimilar” insulin approved in US – potential to come cheaper than other insulins, with launch in December 2016 Lilly/BI recently announced the FDA approval of its long-awaited biosimilar insulin glargine, Basaglar, for type 1 and type 2 diabetes. Basaglar is biologically similar to Sanofi’s basal insulin Lantus (insulin glargine), including the same protein sequence and a similar glucose-lowering effect. While ...

    diabetes May 26, 2018
  • Why Is Lantus Insulin So Expensive

    While everyone’s diabetes treatment plan, medications, and technology may be different, there is one thing we can all agree on: diabetes is expensive. In two previous posts at The Perfect D, I gave some sense of what the bare minimum of care for a U.S. adult with Type 1 diabetes would be and also financial resources and programs to help with the financial burden of living with diabetes. However, this post is about how much it could cost an adul ...

    insulin Dec 23, 2017
  • Lantus Vs Lantus Solostar

    As most of you may know, Lantus, the most commonly prescribed basal insulin, saw its patent protection expire in February of this year. Several new competitors in the basal insulin niche are waiting in the wings, hoping to siphon off some of the $9 billion a year the French firm Sanofi has been earning from Lantus. Two brand new basal insulins currently on deck are Novo Nordisk's Tresiba and a peglispro, from Lilly. Tresiba has been already avail ...

    diabetes May 3, 2018

More in diabetes